ARTICLE | Clinical News
PRO 140: Phase III start
May 18, 2015 7:00 AM UTC
Next month, CytoDyn will begin a 25-week Phase III trial of PRO 140 as part of a highly active anti-retroviral therapy (HAART) regimen in about 300 treatment-experienced patients. CytoDyn said it may ...